Clinical Trials Browser

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00516373 2024-02-22

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Phase 1 Completed

98 enrolled

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00782574 2023-12-21

Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients

Phase 1 Completed

57 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT04375267 2023-11-14

LuPARP

Phase 1 Unknown

18 enrolled

EndocrineNETOther solid neoplasmThoracic

Mesothelioma, Thymoma, Neuroendocrine Tumors

NCT02229656 2023-11-07

Olaparib and Radiotherapy in Head and Neck Cancer

Phase 1 Unknown

12 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms

NCT00535353 2023-08-04

AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

Phase 1 Completed

26 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01921140 2022-11-22

To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours

Phase 1 Completed

60 enrolled

Tumor-Agnostic

Neoplasms

NCT02588105 2022-09-19

AToM

Phase 1 Completed

84 enrolled

Other solid neoplasm

Advanced Solid Tumours

NCT00819221 2022-08-30

AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours

Phase 1 Terminated

44 enrolled

Other solid neoplasm

Solid Tumors

Clinical Trials

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

RADIOSARP

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Study of INCB123667 in Subjects With Advanced Solid Tumors

Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

POLAR

Phase I Comparative Bioavailability Study

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

BISCAY

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma

CONCORDE

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

RadioPARP

PHOEBE

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Selumetinib and Olaparib in Solid Tumors

COD

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

LumOnate

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

PRRT-PARPi

LuPARP

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

ComPAKT

ORCA-2

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients

LuPARP

Olaparib and Radiotherapy in Head and Neck Cancer

AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours

AToM

AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours